Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten

First Turn Management LLC Takes $15.31 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

MarketBeat

Nicholas Investment Partners LP Has $1.78 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

MarketBeat

MSN - MSN

MSN

Axovant Sciences CEO David Hung resigns, shares tumble - Yahoo Singapore News

Yahoo Singapore News

Roivant Sciences (ROIV) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

Vivek Ramaswamy Net Worth: From Pharma CEO to VP Candidate - Business 2 Community

Business 2 Community

Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 - Insider Monkey

Insider Monkey

Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy - Scrip

Scrip

New York State Common Retirement Fund Sells 64221 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World

Defense World

Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's ... - Yahoo Finance

Yahoo Finance

Allspring Global Investments Holdings LLC Grows Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World

Defense World

Roivant Sciences: Cashing In On Vants And Ventures (NASDAQ:ROIV) - Seeking Alpha

Seeking Alpha

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know

Benzinga

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know - Roivant Sciences (NASDAQ - Benzinga

Benzinga

Moderna shares fall after judge sides with Arbutus in patent fight - Yahoo Canada Finance

Yahoo Canada Finance

Roivant launches $1.5 billion share buyback program - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

Roivant reveals positive immune drug data, share buyback plans - Yahoo Finance

Yahoo Finance

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 - Yahoo Finance

Yahoo Finance

Where Roivant Sciences Stands With Analysts

Benzinga

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success (NASDAQ:ROIV) - Seeking Alpha

Seeking Alpha

ROIV Stock Quote Price and Forecast - CNN

CNN

We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability - Simply Wall St

Simply Wall St

Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? - Yahoo Finance

Yahoo Finance

The Analyst Landscape: 4 Takes On Roivant Sciences

Benzinga

Roivant Sciences Ltd President & COO Eric Venker Sells 96950 Shares - Yahoo Finance

Yahoo Finance

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

GlobeNewswire Inc.

MAGA Moolah: How Vivek Ramaswamy got richer during his US presidential campaign - Hindustan Times

Hindustan Times

Why is Vivek Ramaswamy trending on social media - The Times of India

The Times of India

Vivek Ramaswamy drops out of White House race, endorses Donald Trump - Deccan Herald

Deccan Herald

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations

Benzinga

Roivant Sciences Sees Insider Stock Selling - Simply Wall St

Simply Wall St

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy (NASDAQ:ROIV) - Seeking Alpha

Seeking Alpha

Vivek Ramaswamy sells $33M Roivant stock (NASDAQ:ROIV) - Seeking Alpha

Seeking Alpha

Assessing Roivant Sciences: Insights From 5 Financial Analysts

Benzinga

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

GlobeNewswire Inc.

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga

Roche strikes $7.1bn deal for Telavant — Financier Worldwide - Financier Worldwide

Financier Worldwide

Analyst Ratings for Roivant Sciences

Benzinga

ROIV: Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio? - StockNews.com

StockNews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Sandhoff Disease Therapeutics Market is estimated to exhibit a 6% CAGR, bringing its value to US$ 17 - PharmiWeb.com

PharmiWeb.com

Freshfields advises Roivant on sale of Telavant to Roche for $7.1 billion in cash and a near-term milestone payment of ... - Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer

Roche acquires Telavant Holdings for USD 7.1 billion - Medical Dialogues

Medical Dialogues

Swiss pharmaceutical giant Roche announced that it's buying smaller firm Telavant for just over $7 billion - Finimize

Finimize

Insider Trading: Immunovant Stock (NASDAQ:IMVT) Gains on Director's Huge Buy - TipRanks.com - TipRanks

TipRanks

How is Vivek Ramaswamy’s former company doing without him? - The Times of India

The Times of India

Vivek Ramaswamy’s Former Company Is Doing Just Fine Without Him | Mint - Mint

Mint

3 No-Brainer Growth Stocks to Buy in October - The Motley Fool

The Motley Fool

Immunovant to raise $450M on 'potent' falls in IgG levels with MAb in phase I - BioWorld Online

BioWorld Online

Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last? - Zacks Investment Research

Zacks Investment Research